Sökresultat - "Glucagon‐like peptide‐1 receptor agonists"

Denna resultat visas inte till gäster.
Logga in för full Login for full tillgång.

Impact of monotherapy and combination therapy with glucagon-like peptide-1 receptor agonists on exosomal and non-exosomal MicroRNA signatures in type 2 diabetes mellitus: a systematic review.

Yu H; Hubei Key Laboratory of Diabetes and Angiopathy, School of Pharmacy, Xianning Medical College, Hubei University of Science and Technology, Xianning, 437100, Hubei Province, China., Davoudi M; Department of Medical Laboratory Sciences, School of Allied Medical Sciences, Tehran University of Medical Sciences, Tehran, Iran., Sadegh-Nejadi S; Department of Clinical Laboratory, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran., Miao X; Hubei Key Laboratory of Diabetes and Angiopathy, School of Pharmacy, Xianning Medical College, Hubei University of Science and Technology, Xianning, 437100, Hubei Province, China. 345701500@qq.com., Bagherieh M; Ramsar Campus, Mazandaran University of Medical Sciences, Ramsar, Iran. Baqeriyeh@gmail.com., Afrisham R; Department of Medical Laboratory Sciences, School of Allied Medical Sciences, Tehran University of Medical Sciences, Tehran, Iran. rafrisham@sina.tums.ac.ir.

Journal Article; Systematic Review , 2025

Comparison of New-Onset Peripheral Artery Disease in Patients With Type 2 Diabetes Exposed to Sodium-Glucose Cotransporter-2 Inhibitors, Dipeptidyl Peptidase-4 Inhibitors, or Glucagon-Like Peptide-1 Agonists: A Population-Based Cohort Study.

Chou OH; Diabetes Research Unit Cardiovascular Analytics Group Hong Kong China.; Division of Clinical Pharmacology and Therapeutics, Department of Medicine, Li Ka Shing Faculty of Medicine The University of Hong Kong Hong Kong China., Luo Z; Institute of Biomedical Engineering, Department of Engineering Science University of Oxford Oxford UK., Chung CTS; Diabetes Research Unit Cardiovascular Analytics Group Hong Kong China., Chan J; Diabetes Research Unit Cardiovascular Analytics Group Hong Kong China., Li H; School of Life Sciences Chinese University of Hong Kong Hong Kong China., Lakhani I; Diabetes Research Unit Cardiovascular Analytics Group Hong Kong China., Lee S; Diabetes Research Unit Cardiovascular Analytics Group Hong Kong China., Lau DHH; Diabetes Research Unit Cardiovascular Analytics Group Hong Kong China., Zhang Q; Musketeers Foundation Institute of Data Science and Department of Pharmacology and Pharmacy, LKS Faculty of Medicine The University of Hong Kong Hong Kong China., Liu T; Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular Disease, Department of Cardiology, Tianjin Institute of Cardiology Second Hospital of Tianjin Medical University Tianjin China., Wong WT; School of Life Sciences Chinese University of Hong Kong Hong Kong China., Cheung BMY; Division of Clinical Pharmacology and Therapeutics, Department of Medicine, Li Ka Shing Faculty of Medicine The University of Hong Kong Hong Kong China., Lip GYH; Liverpool Centre for Cardiovascular Science at University of Liverpool, Liverpool John Moores University and Liverpool Heart & Chest Hospital Liverpool UK.; Danish Center for Health Services Research, Department of Clinical Medicine Aalborg University Aalborg Denmark., Leung FP; School of Life Sciences Chinese University of Hong Kong Hong Kong China., Tse G; Diabetes Research Unit Cardiovascular Analytics Group Hong Kong China.; School of Nursing and Health Sciences Hong Kong Metropolitan University Hong Kong China., Zhou J; Department of Family Medicine and Primary Care, Li Ka Shing Faculty of Medicine The University of Hong Kong Hong Kong China.; School of Public Health, Li Ka Shing Faculty of Medicine The University of Hong Kong Hong Kong China.; Department of Pharmacology and Pharmacy The University of Hong Kong Hong Kong China.

Journal Article; Comparative Study , 2025

Immunological effects of GLP-1 analogs on female reproduction: Therapeutic perspectives for infertility and recurrent pregnancy loss.

Tavares ACM; Medical Course, Universidade de Fortaleza (UNIFOR), Fortaleza, CE 60.811-905, Brazil., Martins MYM; Medical Course, Universidade de Fortaleza (UNIFOR), Fortaleza, CE 60.811-905, Brazil., de Souza GF; Medical Course, Universidade de Fortaleza (UNIFOR), Fortaleza, CE 60.811-905, Brazil., Lima EM; Medical Course, Universidade de Fortaleza (UNIFOR), Fortaleza, CE 60.811-905, Brazil., Rocha CA; Medical Course, Universidade de Fortaleza (UNIFOR), Fortaleza, CE 60.811-905, Brazil., de Souza LC; Medical Course, Universidade de Fortaleza (UNIFOR), Fortaleza, CE 60.811-905, Brazil., Simões JML; Medical Course, Universidade de Fortaleza (UNIFOR), Fortaleza, CE 60.811-905, Brazil., de Araújo NO; Medical Course, Universidade de Fortaleza (UNIFOR), Fortaleza, CE 60.811-905, Brazil., Cavalcante MB; Medical Course, Universidade de Fortaleza (UNIFOR), Fortaleza, CE 60.811-905, Brazil; Graduate Program in Medical Sciences, Universidade de Fortaleza (UNIFOR), Fortaleza, CE 60.811-905, Brazil; CONCEPTUS - Reproductive Medicine, Fortaleza, CE 60.170-240, Brazil. Electronic address: marcelocavalcante.med@gmail.com.

Journal Article; Review , 2025

Trends in obesity and glucagon-like peptide-1 receptor agonist prescriptions in type 1 diabetes in the United States.

Xu Y; Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA., Echouffo Tcheugui JB; Division of Endocrinology, Diabetes, and Metabolism, Johns Hopkins School of Medicine, Baltimore, Maryland, USA., Coresh J; Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.; Department of Population Health, New York University Grossman School of Medicine, New York, New York, USA., Grams ME; Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.; Department of Population Health, New York University Grossman School of Medicine, New York, New York, USA.; Division of Precision Medicine, Department of Medicine, New York University Grossman School of Medicine, New York, New York, USA., Selvin E; Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA., Fang M; Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA., Shin JI; Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.

Journal Article , 2025

Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes.

McGuire DK; University of Texas Southwestern Medical Center, Dallas.; Parkland Health System, Dallas., Marx N; Clinic for Cardiology, Angiology, and Intensive Care Medicine, Rheinisch-Westfälische Technische Hochschule Aachen University, University Hospital Aachen, Aachen, Germany., Mulvagh SL; Department of Medicine, Division of Cardiology, Dalhousie University, Halifax, NS, Canada., Deanfield JE; Institute of Cardiovascular Sciences, University College London, London., Inzucchi SE; Section of Endocrinology, Yale University School of Medicine, New Haven, CT., Pop-Busui R; Division of Endocrinology, Diabetes, and Clinical Nutrition, Oregon Health and Science University, Portland., Mann JFE; Kuratorium für Heimdialyse Kidney Center, Munich, Germany.; Friedrich Alexander University of Erlangen, Erlangen, Germany., Emerson SS; Department of Biostatistics, University of Washington, Seattle., Poulter NR; Imperial Clinical Trials Unit, Imperial College London, London., Engelmann MDM; Novo Nordisk, Søborg, Denmark., Ripa MS; Novo Nordisk, Søborg, Denmark., Hovingh GK; Novo Nordisk, Søborg, Denmark., Brown-Frandsen K; Novo Nordisk, Søborg, Denmark., Bain SC; Swansea University Medical School, Swansea, United Kingdom., Cavender MA; University of North Carolina School of Medicine, Chapel Hill., Gislum M; Novo Nordisk, Søborg, Denmark., David JP; Novo Nordisk, Søborg, Denmark., Buse JB; University of North Carolina School of Medicine, Chapel Hill.

SOUL Study Group

Journal Article; Multicenter Study; Randomized Controlled Trial , 2025

Semaglutide and walking capacity in people with symptomatic peripheral artery disease and type 2 diabetes (STRIDE): a phase 3b, double-blind, randomised, placebo-controlled trial.

Bonaca MP; CPC Clinical Research, Cardiovascular Division, University of Colorado School of Medicine, Aurora, CO, USA. Electronic address: marc.bonaca@cpcmed.org., Catarig AM; Novo Nordisk, Søborg, Denmark., Houlind K; Department of Vascular Surgery, Lillebaelt Hospital, Kolding, Denmark; Department of Regional Health Research, University of Southern Denmark, Odense, Denmark., Ludvik B; 1st Medical Department and Karl Landsteiner Institute for Obesity and Metabolic Disorders, Landstrasse Clinic, Vienna, Austria., Nordanstig J; Institute of Medicine, Department of Molecular and Clinical Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden., Ramesh CK; Novo Nordisk India, Bangalore, India., Rasouli N; Division of Endocrinology, Metabolism and Diabetes, University of Colorado School of Medicine, Aurora, CO, USA., Sourij H; Interdisciplinary Metabolic Medicine Trials Unit, Division of Endocrinology and Diabetology, Medical University of Graz, Graz, Austria., Videmark A; Novo Nordisk, Søborg, Denmark., Verma S; Division of Cardiovascular Surgery, St Michael's Hospital, University of Toronto, Toronto, ON, Canada.

STRIDE Trial Investigators

Journal Article; Randomized Controlled Trial; Clinical Trial, Phase III; Multicenter Study; Research Support, Non-U.S. Gov't , 2025

SGLT2 Inhibitors and GLP-1 Receptor Agonists in Diabetic Kidney Disease: Evolving Evidence and Clinical Application.

Bae JH; Division of Endocrinology and Metabolism, Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea.; Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea.

Journal Article; Review , 2025

Effects of GLP-1 Receptor Agonists on Paediatric Population in a Real World Setting.

Barajas AG; University of Alabama at Birmingham Marnix E. Heersink School of Medicine, Birmingham, Alabama, USA., Gagnon-Vargas CA; University of Alabama at Birmingham Marnix E. Heersink School of Medicine, Birmingham, Alabama, USA., Schmitt JA; Division of Pediatric Endocrinology and Diabetes, Department of Pediatrics, University of Alabama at Birmingham Marnix E. Heersink School of Medicine, Birmingham, Alabama, USA.

Journal Article , 2025

Newer Glucagon-Like Peptide-1 Receptor Agonists Are Associated With Improved Glycemic Control in US Adults With Type 2 Diabetes: A Population-Level Time Series Analysis.

Lv L; Novo Nordisk Inc, Plainsboro, NJ, USA. Electronic address: lzlv@novonordisk.com., Wang Y; Analysis Group, Inc, Los Angeles, CA, USA., Xie L; Novo Nordisk Inc, Plainsboro, NJ, USA., Noone J; Novo Nordisk Inc, Plainsboro, NJ, USA., Alvarez S; Novo Nordisk Inc, Plainsboro, NJ, USA., Zhang Y; Analysis Group, Inc, New York, NY, USA., Song Y; Analysis Group, Inc, Boston, MA, USA., Rotroff DM; Department of Quantitative Health Sciences, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA; Center for Quantitative Metabolic Research, Cleveland Clinic, Cleveland, OH, USA; Endocrinology and Metabolism Institute, Cleveland Clinic, Cleveland, OH, USA.

Journal Article , 2025

Glucagon-Like Peptide-1 Receptor Agonists in Patients With Durable Left Ventricular Assist Devices.

Elad B; Division of Cardiology, Department of Medicine, Columbia University College of Physicians and Surgeons and NewYork-Presbyterian Hospital, New York, New York, USA., Lee C; Division of Cardiology, Department of Medicine, Columbia University College of Physicians and Surgeons and NewYork-Presbyterian Hospital, New York, New York, USA., Rahman A; Division of Cardiology, Department of Medicine, Columbia University College of Physicians and Surgeons and NewYork-Presbyterian Hospital, New York, New York, USA., Rzechorzek W; Division of Cardiology, Department of Medicine, Columbia University College of Physicians and Surgeons and NewYork-Presbyterian Hospital, New York, New York, USA., DeFilippis EM; Division of Cardiology, Department of Medicine, Columbia University College of Physicians and Surgeons and NewYork-Presbyterian Hospital, New York, New York, USA., Lotan D; Division of Cardiology, Department of Medicine, Columbia University College of Physicians and Surgeons and NewYork-Presbyterian Hospital, New York, New York, USA., Moeller CM; Division of Cardiology, Department of Medicine, Columbia University College of Physicians and Surgeons and NewYork-Presbyterian Hospital, New York, New York, USA., Valledor AF; Division of Cardiology, Department of Medicine, Columbia University College of Physicians and Surgeons and NewYork-Presbyterian Hospital, New York, New York, USA., Rahman S; Division of Cardiology, Department of Medicine, Columbia University College of Physicians and Surgeons and NewYork-Presbyterian Hospital, New York, New York, USA., Baranowska J; Division of Cardiology, Department of Medicine, Columbia University College of Physicians and Surgeons and NewYork-Presbyterian Hospital, New York, New York, USA., Clerkin K; Division of Cardiology, Department of Medicine, Columbia University College of Physicians and Surgeons and NewYork-Presbyterian Hospital, New York, New York, USA., Fried J; Division of Cardiology, Department of Medicine, Columbia University College of Physicians and Surgeons and NewYork-Presbyterian Hospital, New York, New York, USA., Yunis A; Division of Cardiology, Department of Medicine, Columbia University College of Physicians and Surgeons and NewYork-Presbyterian Hospital, New York, New York, USA., Yuzefpolskaya M; Division of Cardiology, Department of Medicine, Columbia University College of Physicians and Surgeons and NewYork-Presbyterian Hospital, New York, New York, USA., Colombo PC; Division of Cardiology, Department of Medicine, Columbia University College of Physicians and Surgeons and NewYork-Presbyterian Hospital, New York, New York, USA., Kaku Y; Division of Cardiothoracic and Vascular Surgery, Department of Surgery, Columbia University College of Physicians and Surgeons and NewYork-Presbyterian Hospital, New York, New York, USA., Naka Y; Division of Cardiothoracic and Vascular Surgery, Department of Surgery, Weill Cornell Medical College, New York, New York, USA., Takeda K; Division of Cardiothoracic and Vascular Surgery, Department of Surgery, Columbia University College of Physicians and Surgeons and NewYork-Presbyterian Hospital, New York, New York, USA., Raikhelkar J; Division of Cardiology, Department of Medicine, Columbia University College of Physicians and Surgeons and NewYork-Presbyterian Hospital, New York, New York, USA., Sayer GT; Division of Cardiology, Department of Medicine, Columbia University College of Physicians and Surgeons and NewYork-Presbyterian Hospital, New York, New York, USA., Uriel N; Division of Cardiology, Department of Medicine, Columbia University College of Physicians and Surgeons and NewYork-Presbyterian Hospital, New York, New York, USA.

Journal Article , 2025

Effect of glucagon-like peptide-1 receptor agonists on the risk of major adverse limb events in patients with type 2 diabetes mellitus: A systematic review and meta-analysis of randomized clinical trials.

Garagoli F; Cardiology Department, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina. Electronic address: fernando.garagoli@hospitalitaliano.org.ar., Masson W; Cardiology Department, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina., Barbagelata L; Cardiology Department, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina., Lobo M; Cardiology Department, Hospital Militar Campo de Mayo, Buenos Aires, Argentina.

Journal Article; Systematic Review; Meta-Analysis; Review , 2025

Semaglutide 2.4 mg in French people living with Class 3 obesity and comorbidities: Baseline characteristics and real-world safety data.

Disse E; CARMEN, INSERM U1060/University of Lyon/INRA U1235, Lyon 1 University, Lyon, France; FORCE, French Obesity Research Centre of Excellence / F-CRIN INSERM network, France. Electronic address: emmanuel.disse@chu-lyon.fr., Aron-Wisnewsky J; Sorbonne Université, Inserm, Unité de recherche Nutrition et Obésités: approches systémiques, NutriOmiques, Paris, France; Assistance Publique Hôpitaux de Paris, Service de Nutrition, Hôpital Pitié-Salpêtrière, 91 Boulevard de l'Hôpital, 75013 Paris, France., Jacobi D; Nantes Université, CHU Nantes, CNRS, INSERM, L'institut du Thorax, F-44000 Nantes, France., Clément K; Sorbonne Université, Inserm, Unité de recherche Nutrition et Obésités: approches systémiques, NutriOmiques, Paris, France; Assistance Publique Hôpitaux de Paris, Service de Nutrition, Hôpital Pitié-Salpêtrière, 91 Boulevard de l'Hôpital, 75013 Paris, France., Laville M; CARMEN, INSERM U1060/University of Lyon/INRA U1235, Lyon 1 University, Lyon, France., Gauthier C; EMNO Dijon, EPSD-Nuvee Dijon, France., Pattou F; Inserm Unit UMR 1190, Islet Cell Transplant Center, University of Lille, Lille, France., Molleville J; Assistance Publique - Hôpitaux de Paris, Service de Soins Médicaux et de Réadaptation en Obésité, Hôpital René Muret, 93270, Sevran, France., Akerib M; Novo Nordisk France, 10-12 Carré Michelet, 92800 Puteaux, France., Jubin L; Assistance Publique Hôpitaux de Paris, Service de Nutrition, Hôpital européen Georges Pompidou, 75015 Paris, France., Gatta-Cherifi B; CHU de Bordeaux, Service Endocrinologie, Diabétologie, Nutrition, INSERMU1215 Université de Bordeaux, Bordeaux, France., Gaborit B; Aix Marseille Univ, INSERM, INRAE, C2VN, Marseille, France; Centre Spécialisé (CSO) PACA Ouest, Department of Endocrinology, Metabolic Diseases and Nutrition, Pôle ENDO, Chemin des Bourrely, APHM, Hôpital Nord, 13915 Marseille, France., Montastier E; Université Paul Sabatier Toulouse III, Institut des Maladies Cardiovasculaires et Métaboliques, UMR1297 CHU Toulouse, France; Service d'Endocrinologie-Nutrition, Hôpital Rangueil, 31 059 Toulouse cedex 9, France., Stenard F; Clinique des Cèdres, 38130 Echirolles, France., Carette C; Université Paris Cité, Assistance Publique Hôpitaux de Paris, Service de Nutrition & CIC 1418, Hôpital européen Georges Pompidou, 75015 Paris, France., Achamrah N; Université Rouen Normandie, INSERM, Normandie Univ, ADEN UMR1073 Nutrition, Inflammation and Microbiota-Gut-Brain Axis, CHU Rouen, CIC-CRB 1404, Department of Nutrition, Rouen, France., Avignon A; Nutrition-Diabetes Department, University Hospital of Montpellier, Montpellier, France., Czernichow S; Assistance Publique Hôpitaux de Paris, Service de Nutrition, Hôpital européen Georges Pompidou, 75015 Paris, France.

SEMAFEAP Study Group

Journal Article , 2025

A retrospective evaluation of glucagon-like peptide-1 receptor agonists in systemic lupus erythematosus patients.

Carlucci PM; Department of Medicine, New York University School of Medicine, New York, NY, USA., Cohen B; Department of Medicine, New York University School of Medicine, New York, NY, USA., Saxena A; Department of Medicine, New York University School of Medicine, New York, NY, USA., Belmont HM; Department of Medicine, New York University School of Medicine, New York, NY, USA., Masson M; Department of Medicine, New York University School of Medicine, New York, NY, USA., Gold HT; Department of Medicine, New York University School of Medicine, New York, NY, USA., Buyon J; Department of Medicine, New York University School of Medicine, New York, NY, USA., Izmirly P; Department of Medicine, New York University School of Medicine, New York, NY, USA.

Journal Article , 2025

First-in-Human Study on Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Escalating Doses of HEC88473, a Novel Dual GLP-1 and FGF21 Receptor Agonist in Healthy and Obese Chinese Subjects.

Zhang H; Phase I Clinical Research Center, The First Hospital of Jilin University, Changchun, 130021, Jilin, China., Li Q; Phase I Clinical Research Center, The First Hospital of Jilin University, Changchun, 130021, Jilin, China., Chen H; Phase I Clinical Research Center, The First Hospital of Jilin University, Changchun, 130021, Jilin, China., Guo L; Dongguan HEC Biopharmaceutical R&D Co., Ltd, Dongguan, China., Li J; Dongguan HEC Biopharmaceutical R&D Co., Ltd, Dongguan, China., Xie C; Dongguan HEC Biopharmaceutical R&D Co., Ltd, Dongguan, China., Yan J; Dongguan HEC Biopharmaceutical R&D Co., Ltd, Dongguan, China.; Sunshine Lake Pharma Co., Ltd, Dongguan, China., Ding Y; Phase I Clinical Research Center, The First Hospital of Jilin University, Changchun, 130021, Jilin, China. dingyanh@jlu.edu.cn.

Journal Article; Clinical Trial, Phase I; Randomized Controlled Trial , 2025

Prescribing patterns of glucagon-like peptide-1 receptor agonists in the Swedish capital region-a register-based cross-sectional study.

Fors A; Department of Pharmacy, Faculty of Pharmacy, Uppsala University, Box 580, 751 23, Uppsala, Sweden., Forslund T; Department of Healthcare Development, Stockholm Region, Public Healthcare Services Committee, Stockholm, Sweden.; Academic Primary Health Care Centre, Stockholm Region, Stockholm, Sweden.; Department of Neurobiology, Care Sciences and Society, Division of Family Medicine and Primary Care, Karolinska Institutet, Solna, Sweden., Sundström A; Department of Pharmacy, Faculty of Pharmacy, Uppsala University, Box 580, 751 23, Uppsala, Sweden.; Division of Use and Information, Swedish Medical Products Agency, Uppsala, Sweden., Wettermark B; Department of Pharmacy, Faculty of Pharmacy, Uppsala University, Box 580, 751 23, Uppsala, Sweden. bjorn.wettermark@uu.se.

Journal Article , 2025

Glucagon-like peptide-1 receptor agonists for the treatment of obstructive sleep apnea: a meta-analysis.

Li M; Xi'an International Medical Center Hospital, Xi'an city, China., Lin H; Xi'an International Medical Center Hospital, Xi'an city, China., Yang Q; Xi'an International Medical Center Hospital, Xi'an city, China., Zhang X; Xi'an International Medical Center Hospital, Xi'an city, China., Zhou Q; Xi'an International Medical Center Hospital, Xi'an city, China., Shi J; Xi'an International Medical Center Hospital, Xi'an city, China., Ge F; Xi'an International Medical Center Hospital, Xi'an city, China.

Journal Article; Meta-Analysis , 2025

Glucagon-like Peptide-1 receptor agonists for obstructive sleep apnea in patients with obesity and type 2 diabetes mellitus: a systematic review and meta-analysis.

Yang R; School of Traditional Chinese Medicine, Beijing University of Chinese Medicine, Beijing, China.; Key Laboratory of Health Cultivation of the Ministry of Education, Beijing University of Chinese Medicine, Beijing, China.; Key Laboratory of Health Cultivation of Beijing, Beijing University of Chinese Medicine, Beijing, China., Zhang L; School of Traditional Chinese Medicine, Beijing University of Chinese Medicine, Beijing, China.; Key Laboratory of Health Cultivation of the Ministry of Education, Beijing University of Chinese Medicine, Beijing, China.; Key Laboratory of Health Cultivation of Beijing, Beijing University of Chinese Medicine, Beijing, China., Guo J; Key Laboratory of Health Cultivation of the Ministry of Education, Beijing University of Chinese Medicine, Beijing, China.; Key Laboratory of Health Cultivation of Beijing, Beijing University of Chinese Medicine, Beijing, China.; The First Clinical Medical College, Shaanxi University of Chinese Medicine, Xianyang, China., Wang N; School of Traditional Chinese Medicine, Beijing University of Chinese Medicine, Beijing, China.; Key Laboratory of Health Cultivation of the Ministry of Education, Beijing University of Chinese Medicine, Beijing, China.; Key Laboratory of Health Cultivation of Beijing, Beijing University of Chinese Medicine, Beijing, China., Zhang Q; School of Traditional Chinese Medicine, Beijing University of Chinese Medicine, Beijing, China.; Key Laboratory of Health Cultivation of the Ministry of Education, Beijing University of Chinese Medicine, Beijing, China.; Key Laboratory of Health Cultivation of Beijing, Beijing University of Chinese Medicine, Beijing, China., Qi Z; School of Traditional Chinese Medicine, Beijing University of Chinese Medicine, Beijing, China.; Key Laboratory of Health Cultivation of the Ministry of Education, Beijing University of Chinese Medicine, Beijing, China.; Key Laboratory of Health Cultivation of Beijing, Beijing University of Chinese Medicine, Beijing, China., Wu L; Key Laboratory of Health Cultivation of the Ministry of Education, Beijing University of Chinese Medicine, Beijing, China.; Key Laboratory of Health Cultivation of Beijing, Beijing University of Chinese Medicine, Beijing, China., Qin L; Key Laboratory of Health Cultivation of the Ministry of Education, Beijing University of Chinese Medicine, Beijing, China.; Key Laboratory of Health Cultivation of Beijing, Beijing University of Chinese Medicine, Beijing, China.; Department of Science and Technology, Beijing University of Chinese Medicine, Beijing, China., Liu T; Key Laboratory of Health Cultivation of the Ministry of Education, Beijing University of Chinese Medicine, Beijing, China. thliu@vip.163.com.; Key Laboratory of Health Cultivation of Beijing, Beijing University of Chinese Medicine, Beijing, China. thliu@vip.163.com.

Journal Article; Systematic Review; Meta-Analysis; Review , 2025

Impact of GLP-1 Receptor Agonists on Alcohol-Related Liver Disease Development and Progression in Alcohol Use Disorder.

Kuo CC; Department of Internal Medicine, Chi Mei Medical Center, Tainan, Taiwan., Li CH; Department of Physical Medicine and Rehabilitation, Chi Mei Medical Center, Tainan, Taiwan., Chuang MH; Department of Internal Medicine, Chi Mei Medical Center, Tainan, Taiwan., Huang PY; Department of Internal Medicine, Chi Mei Medical Center, Tainan, Taiwan., Kuo HT; Department of Internal Medicine, Chi Mei Medical Center, Tainan, Taiwan.; School of Medicine, College of Medicine, National Sun Yat-Sen University, Kaohsiung, Taiwan., Lai CC; School of Medicine, College of Medicine, National Sun Yat-Sen University, Kaohsiung, Taiwan.; Department of Intensive Care Medicine, Chi Mei Medical Center, Tainan, Taiwan.

Journal Article , 2025

Effects of Glucagon-Like Peptide-1 Receptor Agonists on Upper Gastrointestinal Endoscopy: A Meta-Analysis.

Facciorusso A; Section of Gastroenterology, Department of Medical and Surgical Sciences, University of Foggia, Foggia, Italy; Clinical Effectiveness Research Group, Institute of Health and Society, Faculty of Medicine, University of Oslo, Oslo, Norway. Electronic address: antionio.facciorusso@virgilio.it., Ramai D; Division of Gastroenterology, Hepatology and Endoscopy, Brigham and Women's Hospital, Boston, Massachusetts., Dhar J; Department of Gastroenterology, Postgraduate Institute of Medical Education and Research, Chandigarh, India., Samanta J; Department of Gastroenterology, Postgraduate Institute of Medical Education and Research, Chandigarh, India., Chandan S; Center for Interventional Endoscopy, Advent Health, Orlando, Florida., Gkolfakis P; Department of Gastroenterology, Konstantopoulio-Patision General Hospital of Nea Ionia, Athens, Greece., Crinò SF; Gastroenterology and Digestive Endoscopy Unit, Pancreas Institute, Department of Medicine, University Hospital of Verona, Verona, Italy., Maida M; Department of Medicine and Surgery, School of Medicine and Surgery, University of Enna Kore, Enna, Italy., Anderloni A; Endoscopy, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy., Boskoski I; Digestive Endoscopy Unit, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma, Italy., Triantafyllou K; Hepatogastroenterology Unit, Second Department of Propaedeutic Internal Medicine, Medical School, Attikon University General Hospital, National and Kapodastrian University of Athens, Athens, Greece., Dinis-Ribeiro M; Porto Comprehensive Cancer Center and RISE@CI-IPO, University of Porto, Porto, Portugal; Gastroenterology Department, Portuguese Oncology Institute of Porto, Porto, Portugal., Hassan C; Department of Gastroenterology, IRCCS Humanitas Research Hospital, Rozzano, Italy; Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Italy., Fuccio L; Department of Medical Sciences and Surgery, University of Bologna, Bologna, Italy., Arvanitakis M; Department of Gastroenterology, Digestive Oncology and Hepatopancreatology, HUB Hôpital Erasme, Brussels, Belgium.

Journal Article; Meta-Analysis; Systematic Review , 2025